化疗引起的恶心和呕吐。 - Suppr

Suppr

超能文献

Chemotherapy-induced nausea and vomiting.

作者信息

Hesketh Paul J

机构信息

Caritas St. Elizabeth's Medical Center, Boston, MA 02135, USA.

出版信息

N Engl J Med. 2008 Jun 5;358(23):2482-94. doi: 10.1056/NEJMra0706547.

DOI:10.1056/NEJMra0706547

PMID:18525044

Abstract

摘要

相似文献

Chemotherapy-induced nausea and vomiting.

N Engl J Med. 2008 Jun 5;358(23):2482-94. doi: 10.1056/NEJMra0706547.

Pathogenesis-based treatment of chemotherapy-induced nausea and vomiting--two new agents.

J Support Oncol. 2003 Jul-Aug;1(2):89-103.

Update on the management of chemotherapy-related nausea and vomiting: an emphasis on the new class of agents--neurokinin-1 receptor antagonists.

Clin Adv Hematol Oncol. 2006 Jul;4(7):507-8.

Neurokinin antagonism and chemotherapy-induced emesis.

Am J Gastroenterol. 1999 Nov;94(11):3368-9. doi: 10.1111/j.1572-0241.1999.03368.x.

Palonosetron: a unique 5-HT3 receptor antagonist indicated for the prevention of acute and delayed chemotherapy-induced nausea and vomiting.

Clin Adv Hematol Oncol. 2004 May;2(5):284-9.

Addition of the oral NK1 antagonist aprepitant to standard antiemetics provides protection against nausea and vomiting during multiple cycles of cisplatin-based chemotherapy.

J Clin Oncol. 2003 Nov 15;21(22):4105-11. doi: 10.1200/JCO.2003.10.128. Epub 2003 Oct 14.

Antiemetic drugs.

Medsurg Nurs. 2009 Sep-Oct;18(5):309-13; quiz 314.

Chemotherapy-induced nausea and vomiting: antiemetic trials that impacted clinical practice.

J Oncol Pharm Pract. 2010 Dec;16(4):233-44. doi: 10.1177/1078155209354655. Epub 2010 Jan 19.

[Prevention of nausea and vomiting. Aprepitant, the first therapeutic acting NK-1 receptor antagonist].

Pharm Unserer Zeit. 2007;36(5):373-80. doi: 10.1002/pauz.200700234.

Fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting.

Expert Rev Anticancer Ther. 2012 Feb;12(2):139-50. doi: 10.1586/era.11.199.

引用本文的文献

Inhaling Peppermint Essential Oil as a Promising Complementary Therapy in the Treatment of Nausea and Vomiting.

J Clin Med. 2025 Jul 17;14(14):5069. doi: 10.3390/jcm14145069.

Refractory Nausea and Vomiting Due to Central Nervous System Injury: A Focused Review.

Life (Basel). 2025 Jun 27;15(7):1021. doi: 10.3390/life15071021.

Neurokinin-1 receptor antagonists in the current management of chemotherapy-induced nausea and vomiting.

Front Med. 2025 Jul 5. doi: 10.1007/s11684-025-1140-8.

Mechanism and Predictive Role of NUB1 Protein in Oestrogen Receptor Pathway of FEC-Treated Breast Cancer Patients.

Biomedicines. 2025 May 27;13(6):1307. doi: 10.3390/biomedicines13061307.

Incidence and Risk Factors of Platinum-Based Chemotherapy-Induced Nausea and Vomiting: A Systematic Review and Meta-Analysis.

Curr Oncol. 2025 May 31;32(6):325. doi: 10.3390/curroncol32060325.

Hypophagia and body weight loss by tirzepatide are accompanied by fewer GI adverse events compared to semaglutide in preclinical models.

Sci Adv. 2025 Jun 20;11(25):eadu1589. doi: 10.1126/sciadv.adu1589. Epub 2025 Jun 18.

Omission of dexamethasone in prophylaxis for highly emetogenic chemotherapy in patients with breast cancer.

Einstein (Sao Paulo). 2025 May 12;23:eAO1124. doi: 10.31744/einstein_journal/2025AO1124. eCollection 2025.

Comprehensive gut microbiota and metabolomics combined with network pharmacology reveal the effects of acupuncture treatment for chemotherapy-induced nausea and vomiting.

Transl Gastroenterol Hepatol. 2025 Apr 14;10:26. doi: 10.21037/tgh-24-35. eCollection 2025.

The Pharmacological and Clinical Roles of Antiemetics: A Narrative Review.

Cureus. 2025 Jan 13;17(1):e77370. doi: 10.7759/cureus.77370. eCollection 2025 Jan.

Efficacy and safety of ondansetron orally soluble pellicle for preventing moderate- to high-emetic risk chemotherapy-induced nausea and vomiting.

BMC Cancer. 2025 Jan 6;25(1):16. doi: 10.1186/s12885-024-13406-z.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验